Moleculin Biotech, Inc. cotiza a 0.42 USD y tiene una capitalización bursátil de $9M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia an…
| Periodo | 2026-05 | 2025-11 | 2025-08 | 2025-05 |
|---|---|---|---|---|
| Real | $-3.54 | $-17.00 | $-12.25 | $-17.25 |
| Estimado | $-1.66 | $-6.58 | $-10.08 | $-13.87 |
| Sorpresa | -113.3% | -158.4% | -21.5% | -24.4% |
| Métrica | MBRX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -223.6% | -40.4% | -183.2% |
| ROA | -151.7% | -32.0% | -119.7% |
| Current Ratio | 1.41 | 2.84 | -1.43 |
| Debt / Equity | — | 0.28 | — |